import json
import os

articles_data = [
    {
        "pmid": "42323953",
        "title": "Contrastive Machine Learning to Quantify Hypertensive Multiorgan Damage and Identify New Disease Phenotypes: A Multinational Multimodal Study",
        "journal": "Circulation",
        "pub_date": "2026-06-21",
        "topic": "Hypertension Epidemiology",
        "topic_num": 1,
        "tier": "1",
        "if_estimate": ">35",
        "article_type": "Original Research",
        "findings": (
            "This multinational, multimodal study enrolled 27,099 UK Biobank participants and analyzed 566 imaging and non-imaging variables using a novel semisupervised contrastive trajectory inference (cTI) machine learning framework to characterize hypertensive multiorgan damage. "
            "The primary endpoint was the ability of the derived global organ damage score (HyperScore) to discriminate severe end-organ disease, achieving an AUC of 0.964 (95% CI 0.941–0.987), substantially outperforming conventional blood pressure-based stratification. "
            "External validation on 5,507 ARIC study participants confirmed the generalizability and robustness of the HyperScore across different populations and geographic contexts. "
            "The HyperTrajectory algorithm identified six clinically distinct hypertensive phenotypes: cardiac, lipoprotein, atherothrombosis, brain, cardiorenal, and hepatic, each with distinct organ damage profiles and survival trajectories. "
            "Critically, survival stratification by HyperScore was statistically significant (p&lt;0.001), whereas standard blood pressure stratification failed to reach significance, underscoring the limitation of BP alone as a risk surrogate. "
            "Notable limitations include the observational design, potential selection bias of UK Biobank volunteers (generally healthier than the general population), and the cross-sectional imaging assessments that preclude causal inference."
        ),
        "implications": (
            "This study challenges the paradigm that blood pressure levels alone are sufficient for cardiovascular risk stratification in hypertension, suggesting that multiorgan damage scoring could redefine treatment intensification thresholds in future guidelines. "
            "From a Medical Affairs perspective, this reinforces the value of positioning antihypertensive therapies not merely by BP reduction but by demonstrable organ protection, opening new avenues for outcome-based product differentiation. "
            "Engaging KOLs around the HyperScore and HyperTrajectory framework presents an opportunity to shape the next cycle of ESC/ACC/AHA hypertension guideline discussions around phenotype-driven treatment algorithms."
        ),
    },
    {
        "pmid": "42323930",
        "title": "Redefining the phenomenon: risk of preeclampsia in white-coat hypertension during the second half of pregnancy in a high-risk cohort",
        "journal": "Pregnancy Hypertension",
        "pub_date": "2026-06-21",
        "topic": "Hypertension Epidemiology",
        "topic_num": 1,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Original Research",
        "findings": (
            "This retrospective cohort study enrolled 1,415 high-risk pregnant women between 20 and 34 weeks of gestation and classified blood pressure phenotypes using both office BP measurement and 24-hour ambulatory blood pressure monitoring (ABPM), including daytime and nighttime readings. "
            "White-coat hypertension (WCH) was identified in 2% of the cohort (28 women), with composite maternal outcomes (preeclampsia, eclampsia, or HELLP syndrome) observed in 10.2% of normotensive women, 7.1% in WCH, 30.5% in masked hypertension, and 40.7% in sustained hypertension. "
            "After multivariate adjustment, WCH was not associated with increased maternal risk compared to normotension (OR 0.81; 95% CI 0.19–3.52), representing a non-significant result that challenges prior assumptions about WCH in pregnancy. "
            "Adverse fetal outcomes, including preterm birth, small for gestational age, and perinatal mortality, were also not significantly elevated in the WCH group. "
            "The inclusion of nighttime BP via full ABPM appears critical: when WCH is properly defined to exclude masked nocturnal hypertension, its prognosis appears benign, which has direct implications for clinical management and avoidance of unnecessary pharmacological intervention. "
            "Key limitations include the small WCH subgroup (n=28) limiting statistical power, the retrospective design, and referral center bias inherent to a high-risk obstetric cohort."
        ),
        "implications": (
            "These findings support the use of full 24-hour ABPM including nighttime readings as the gold standard for phenotyping hypertension in pregnancy, with implications for future obstetric hypertension guideline revisions emphasizing ABPM-based classification. "
            "For product positioning, this reinforces the clinical value of ambulatory monitoring technologies and underscores the need for antihypertensive therapy to target confirmed sustained or masked hypertension rather than white-coat phenomena in pregnant patients. "
            "Medical Affairs teams should engage maternal-fetal medicine KOLs to discuss ABPM implementation pathways in high-risk obstetric centers, positioning evidence-based phenotyping as a prerequisite to treatment decisions."
        ),
    },
    {
        "pmid": "42322785",
        "title": "Comprehensive evaluation of secondary causes of hypertension: Integrated screening for obstructive sleep apnea and primary aldosteronism",
        "journal": "Sleep Medicine",
        "pub_date": "2026-06-19",
        "topic": "Hypertension Epidemiology",
        "topic_num": 1,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Original Research",
        "findings": (
            "This cross-sectional study systematically screened 131 hypertensive adults (mean age 47.8±12.5 years; 63.4% male) for five secondary causes of hypertension: obstructive sleep apnea (OSA), primary aldosteronism (PA), renal artery stenosis, pheochromocytoma, and aortic coarctation, using level I polysomnography and biochemical aldosterone/renin ratio testing. "
            "Moderate-to-severe OSA (AHI ≥15 events/hour) was identified in 84.5% of participants, making it by far the most prevalent identifiable secondary contributor to hypertension in this cohort. "
            "Primary aldosteronism was confirmed in 8.4% of patients and was more commonly identified in leaner individuals and those with resistant hypertension, replicating findings from prior specialty referral studies. "
            "All other secondary causes (renal artery stenosis, pheochromocytoma, coarctation) each accounted for less than 2% of cases individually. "
            "Importantly, OSA, PA, and resistant hypertension frequently coexisted in the same patients, suggesting an additive or synergistic pathophysiological relationship that complicates management and may require multi-disciplinary therapeutic approaches. "
            "Limitations include the cross-sectional design precluding causal inference, the single-center referral population which may overrepresent complex or resistant cases, and the absence of long-term outcome data following secondary cause treatment."
        ),
        "implications": (
            "The exceptionally high OSA prevalence (84.5%) in hypertensive patients underscores the clinical imperative for routine sleep disorder screening in hypertension management protocols, a gap that current international guidelines address inadequately. "
            "This study supports positioning CPAP therapy and PA-specific treatments (mineralocorticoid receptor antagonists) as first-line adjunctive interventions in resistant hypertension, creating a clear clinical rationale for combination therapeutic strategies. "
            "Medical Affairs should collaborate with sleep medicine and endocrinology KOLs to develop cross-specialty hypertension management pathways, particularly targeting resistant hypertension centers where secondary causes are disproportionately prevalent."
        ),
    },
    {
        "pmid": "42322216",
        "title": "Management of hypertensive disorders in pregnancy",
        "journal": "Current Opinion in Obstetrics &amp; Gynecology",
        "pub_date": "2026-06-23",
        "topic": "Hypertension Epidemiology",
        "topic_num": 1,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Review",
        "findings": (
            "This comprehensive review synthesizes current evidence for the diagnosis, management, and prevention of hypertensive disorders of pregnancy (HDP), encompassing chronic hypertension, gestational hypertension, preeclampsia, and eclampsia across the antenatal and postpartum periods. "
            "A central finding is that treatment of chronic hypertension to a target below 140/90 mmHg during pregnancy is now supported by recent randomized controlled trial evidence, representing a meaningful tightening of management thresholds versus older permissive guidance. "
            "Diagnostic criteria for preeclampsia are evolving to incorporate circulating biomarkers, specifically soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) ratios, potentially enabling earlier and more accurate identification of at-risk pregnancies. "
            "The postpartum period is increasingly recognized as a critical and underserved window for blood pressure surveillance and management, with evidence that a significant proportion of maternal cardiovascular morbidity occurs after delivery. "
            "The review proposes strategies including lower BP treatment thresholds postpartum and dedicated hypertension referral clinics for women with HDP, citing evidence gaps regarding optimal antihypertensive thresholds in the postpartum period as a priority for future research. "
            "Key limitations of the evidence base include heterogeneity in HDP classification systems across studies, limited data on long-term maternal cardiovascular outcomes following HDP, and underrepresentation of low- and middle-income country populations."
        ),
        "implications": (
            "The endorsement of tighter BP targets (&lt;140/90 mmHg) in pregnancy and the proposed extension of management into the postpartum period will likely inform the next generation of obstetric hypertension guidelines from ISSHP, ESC, and ACOG. "
            "The emerging role of sFlt-1/PlGF biomarker-guided diagnosis presents a potential indication expansion opportunity for antihypertensive products used earlier in the preeclampsia continuum. "
            "Medical Affairs teams should proactively engage with maternal health KOLs and guideline committee members around postpartum hypertension management pathways, where current evidence gaps represent both unmet clinical need and research investment opportunities."
        ),
    },
    {
        "pmid": "42323443",
        "title": "A machine learning-based framework for predicting hypertension using serum hematological factors",
        "journal": "Scientific Reports",
        "pub_date": "2026-06-20",
        "topic": "Hypertension Epidemiology",
        "topic_num": 1,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Original Research",
        "findings": (
            "This study utilized the MASHAD (Mashhad Stroke and Heart Atherosclerotic Disorder) prospective cohort (2010–2020) comprising 4,923 participants (3,033 without and 1,890 with incident hypertension) to develop and validate a machine learning framework for hypertension prediction based on serum hematological biomarkers and clinical variables. "
            "Multiple ML algorithms were evaluated, with XGBoost achieving the best discriminative performance (ROC-AUC 0.66; 95% CI 0.63–0.69), a modest but statistically significant result that exceeded logistic regression and other classical approaches. "
            "The most influential predictors in the model were age, body mass index (BMI), red blood cell (RBC) count, and mean corpuscular volume (MCV), highlighting the metabolic and inflammatory dimensions of hypertension pathogenesis. "
            "Additional hematological variables contributing to model performance included white blood cell count (WBC), platelet count (PLT), red cell distribution width (RDW), platelet distribution width (PDW), and neutrophil-to-lymphocyte ratio (NLR). "
            "The model demonstrated stability across training and test sets with minimal overfitting, lending confidence to the reproducibility of findings, though the absolute AUC of 0.66 indicates limited individual-level predictive utility in isolation. "
            "Limitations include reliance on a single Iranian cohort potentially limiting generalizability, the moderate AUC suggesting incomplete capture of hypertension's multifactorial etiology, and the absence of validation in diverse external populations."
        ),
        "implications": (
            "While the predictive accuracy (AUC 0.66) is insufficient for standalone clinical use, the identification of routine hematological markers as hypertension predictors opens avenues for integrating CBC-based risk scores into primary care screening algorithms at low incremental cost. "
            "From a product positioning standpoint, these findings reinforce the narrative that hypertension risk exists along a continuum linked to systemic inflammation and metabolic dysregulation, supporting therapeutic strategies that address these upstream pathways. "
            "Medical Affairs should monitor developments in ML-based hypertension risk stratification tools, as regulatory approval of such algorithms could reshape primary prevention strategies and shift treatment initiation thresholds."
        ),
    },
    {
        "pmid": "42323108",
        "title": "Phenotyping of pulmonary arterial hypertension associated with congenital heart disease using latent class analysis: insights from a national prospective registry",
        "journal": "Chest",
        "pub_date": "2026-06-20",
        "topic": "Hypertension Epidemiology",
        "topic_num": 1,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Original Research",
        "findings": (
            "This study analyzed 889 adult patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) from a multicenter national prospective registry, applying latent class analysis (LCA) to 28 clinical, laboratory, and hemodynamic variables to identify distinct disease phenogroups. "
            "Among patients with post-tricuspid shunts, LCA identified four phenogroups, with the 'hyperkinetic' Group 2 demonstrating a statistically significant differential benefit from combination PAH-specific therapy (interaction p=0.026), suggesting a phenotype-specific treatment response. "
            "In the pre-tricuspid shunt subset, LCA similarly revealed four phenogroups, with an 'older male with comorbidities' Group 2 exhibiting significantly higher all-cause mortality compared to other phenogroups (interaction p=0.037). "
            "Ten-year survival differed significantly across phenogroups in both subsets, validating the clinical relevance of the LCA-derived classification beyond traditional hemodynamic parameters. "
            "These findings indicate that LCA can uncover clinically actionable heterogeneity within PAH-CHD that is not captured by current classification systems, with treatment effect modification by phenogroup representing a potential avenue for precision therapy. "
            "Limitations include the observational registry design with potential confounding, heterogeneity in data completeness across centers, and the need for prospective validation of the phenogroup-treatment interaction findings before clinical implementation."
        ),
        "implications": (
            "The demonstration of significant phenogroup-treatment interactions within PAH-CHD has direct implications for future randomized trial design, supporting stratified enrollment by LCA-defined phenotype to detect differential treatment effects. "
            "From a product positioning perspective, these findings strengthen the scientific rationale for precision medicine approaches to PAH therapy, particularly combination regimens targeted to hemodynamically distinct patient subsets. "
            "Medical Affairs engagement with PAH KOLs and congenital cardiology societies should prioritize dissemination of phenotyping frameworks, as registry-based phenotyping could inform the next generation of PAH treatment algorithms and reimbursement criteria."
        ),
    },
    {
        "pmid": "42324170",
        "title": "Association between hair loss and cardiometabolic diseases in Chinese adults: a cross-sectional analysis in Tianning Cohort",
        "journal": "Journal of Epidemiology",
        "pub_date": "2026-06-20",
        "topic": "Hypertension Epidemiology",
        "topic_num": 1,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Original Research",
        "findings": (
            "This cross-sectional study enrolled 5,020 Chinese adults from the Tianning Cohort and assessed hair loss severity using the Modified Hamilton-Norwood scale in males and the Savin scale in females, examining associations with hypertension, diabetes, dyslipidemia, and cardiometabolic multimorbidity. "
            "Mild hair loss was associated with a 29% higher odds of hypertension (OR=1.29; 95% CI 1.08–1.54) compared to individuals without hair loss, after adjustment for major confounders including age, sex, BMI, and lifestyle factors. "
            "Severe hair loss was associated with a 48% higher odds of hypertension (OR=1.48; 95% CI 1.16–1.89), demonstrating a dose-response relationship between hair loss severity and hypertensive risk. "
            "Severe hair loss was also associated with 44% higher odds of diabetes (OR=1.44; 95% CI 1.11–1.86) and 30% higher odds of cardiometabolic multimorbidity (OR=1.30; 95% CI 1.02–1.65), suggesting shared pathophysiological mechanisms. "
            "No statistically significant association was found between hair loss and dyslipidemia after full covariate adjustment, indicating that the cardiometabolic signal may be mediated through pathways other than lipid dysregulation, potentially including androgen excess, insulin resistance, and chronic inflammation. "
            "Limitations include the cross-sectional design precluding causal inference, potential misclassification of hair loss severity, and the single-site Chinese cohort limiting external generalizability."
        ),
        "implications": (
            "The dose-response association between hair loss and hypertension risk adds to a growing body of evidence linking androgenetic alopecia to cardiovascular risk factor burden, and may support the inclusion of hair loss assessment as a simple, non-invasive cardiovascular risk indicator in primary care screening. "
            "From a Medical Affairs standpoint, these findings reinforce the systemic nature of hypertension risk factors and support educational initiatives that raise awareness among dermatologists about cardiometabolic comorbidity screening in patients presenting with alopecia. "
            "This epidemiological association warrants further prospective investigation and could stimulate KOL interest in cross-specialty hypertension prevention initiatives bridging dermatology and cardiology."
        ),
    },
    {
        "pmid": "42323573",
        "title": "Comorbidities, health-related quality of life and its associated factors among people living with HIV/AIDS in Gandaki Province of Nepal",
        "journal": "BMC Public Health",
        "pub_date": "2026-06-20",
        "topic": "Hypertension Epidemiology",
        "topic_num": 1,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Original Research",
        "findings": (
            "This cross-sectional study enrolled 337 people living with HIV/AIDS (PLHIV) attending an antiretroviral therapy (ART) center in Gandaki Province, Nepal, assessing health-related quality of life (HRQoL) using a validated instrument and documenting comorbidity prevalence. "
            "Mean HRQoL score was 6.25±1.87, with 52.2% of participants classified as having poor quality of life, indicating a substantial HRQoL burden in this ART-treated population. "
            "At least one comorbidity was identified in 28.2% of PLHIV, with hypertension being the most frequent at 36.8% among those with comorbidities, followed by diabetes (33.7%), tuberculosis (14.9%), hepatitis B (10.6%), and hepatitis C (4.3%). "
            "PLHIV with comorbidities had higher odds of poor HRQoL (adjusted OR=1.65; 95% CI 0.98–2.78), with the confidence interval crossing 1.0, indicating a trend towards significance that fell short of the conventional threshold, possibly due to limited sample size. "
            "The predominance of hypertension as the leading comorbidity in this HIV-positive population reflects the growing recognition of HIV as an independent cardiovascular risk factor, driven by chronic inflammation, immune activation, and ART-related metabolic effects. "
            "Key limitations include the single-center cross-sectional design, potential social desirability bias in self-reported outcomes, and limited generalizability beyond the study setting."
        ),
        "implications": (
            "The high prevalence of hypertension (36.8%) among PLHIV with comorbidities underscores the urgent need for integrated cardiovascular risk management within HIV care programs, especially as HIV-positive populations age and ART success extends life expectancy. "
            "This creates a strategic Medical Affairs opportunity to position antihypertensive therapies with favorable metabolic profiles as preferred options in HIV-positive patients receiving ART, where drug-drug interactions and metabolic side effects are clinical priorities. "
            "KOL engagement efforts should target HIV/infectious disease specialists and cardiologists managing PLHIV, advocating for cardiovascular risk factor screening as a standard component of HIV longitudinal care."
        ),
    },
    {
        "pmid": "42324102",
        "title": "Efficacy and safety of ticagrelor versus clopidogrel after PCI in patients with acute coronary syndrome without standard modifiable cardiovascular risk factors [SMuRF-less]",
        "journal": "Zhonghua Xin Xue Guan Bing Za Zhi",
        "pub_date": "2026-06-24",
        "topic": "Hypertension Epidemiology",
        "topic_num": 1,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Original Research",
        "findings": (
            "This retrospective cohort study analyzed 3,323 SMuRF-less ACS patients (defined by the absence of hypertension, diabetes, hyperlipidemia, and smoking) undergoing percutaneous coronary intervention (PCI), with 2,694 (81.1%) receiving clopidogrel and 629 (18.9%) receiving ticagrelor for dual antiplatelet therapy. "
            "The primary efficacy endpoint—major adverse cardiovascular events (MACE) at 12 months—did not differ between groups: ticagrelor 1.4% vs. clopidogrel 2.0% (HR=0.90; 95% CI 0.43–1.87; p=0.778), suggesting comparable ischemic protection in this low-risk subgroup. "
            "The primary safety endpoint—BARC 2–5 bleeding events—was significantly higher in the ticagrelor group (9.2% vs. 5.9%; HR=1.79; 95% CI 1.30–2.47; p&lt;0.001), indicating a substantially elevated bleeding risk without corresponding ischemic benefit in SMuRF-less patients. "
            "The absence of standard modifiable risk factors (SMuRFs) in this cohort may reflect a fundamentally different atherogenic mechanism (e.g., genetic, inflammatory, or plaque-based) where more potent antiplatelet therapy confers less incremental benefit. "
            "These findings challenge the universal application of guidelines recommending ticagrelor over clopidogrel in ACS post-PCI, suggesting that SMuRF-less patients may represent a subset where the bleeding risk-benefit calculation favors less aggressive antiplatelet regimens. "
            "Limitations include the retrospective design with inherent confounding, potential selection bias in antiplatelet assignment, the predominant Chinese cohort, and limited generalizability to other populations."
        ),
        "implications": (
            "The unfavorable safety profile of ticagrelor in SMuRF-less ACS patients has meaningful implications for guideline discussions around personalized antiplatelet therapy selection, advocating for risk-stratified rather than universal P2Y12 inhibitor recommendations. "
            "From a Medical Affairs perspective, these data support the narrative that low-risk ACS patients—including those without hypertension—may not derive the same net benefit from more potent antiplatelet agents, reinforcing the importance of individualized benefit-risk assessment. "
            "This study should be highlighted in scientific exchange with interventional cardiology KOLs and at cardiovascular pharmacotherapy meetings to stimulate discussion about antiplatelet therapy de-escalation strategies in appropriately selected low-risk patients."
        ),
    },
    {
        "pmid": "42323016",
        "title": "Chlorthalidone vs. Hydrochlorothiazide in Hypertension Management: Lessons for Guiding Clinical Practice",
        "journal": "The American Journal of the Medical Sciences",
        "pub_date": "2026-06-20",
        "topic": "Clinical Trials and Guidelines",
        "topic_num": 6,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Editorial",
        "findings": (
            "This editorial reviews the comparative evidence base for chlorthalidone versus hydrochlorothiazide (HCTZ) in hypertension management, synthesizing available data from head-to-head comparative effectiveness studies, pharmacokinetic analyses, and cardiovascular outcome trials. "
            "Chlorthalidone is recognized for its superior 24-hour blood pressure-lowering effect and significantly longer plasma half-life (~45–60 hours vs. ~8–15 hours for HCTZ), which translates to more consistent nocturnal and early-morning BP control. "
            "However, chlorthalidone is also associated with higher rates of electrolyte abnormalities, particularly hypokalemia and hyponatremia, requiring closer biochemical monitoring in clinical practice compared to HCTZ. "
            "The editorial highlights that despite evidence favoring chlorthalidone on BP efficacy and cardiovascular outcomes from observational data, HCTZ remains more widely prescribed globally, reflecting prescribing inertia and formulary limitations. "
            "The authors call for updated guideline clarity from major cardiovascular societies (ESC, ACC/AHA) to explicitly address the chlorthalidone vs. HCTZ choice and provide practical dosing and monitoring recommendations, noting that current guidance remains insufficiently specific. "
            "Limitations inherent to the editorial format include the absence of original data, potential selection bias in cited literature, and the challenge of translating population-level findings to individual patient management decisions."
        ),
        "implications": (
            "The ongoing chlorthalidone vs. HCTZ debate represents an active guideline evolution area where Medical Affairs can facilitate evidence dissemination to primary care and cardiology stakeholders, particularly as updated ESC and ACC/AHA guidelines are anticipated. "
            "From a product positioning standpoint, antihypertensive regimens incorporating chlorthalidone could be positioned on the basis of superior nocturnal BP control and cardiovascular outcome data, with metabolic monitoring support programs addressing the electrolyte concern. "
            "KOL engagement should include hypertension specialists and guideline authors to ensure that comparative thiazide evidence is accurately represented in upcoming clinical practice documents and educational programs."
        ),
    },
    {
        "pmid": "42323064",
        "title": "Why Is Hypertension Reaching the Cardiologist? Observations From a Community Practice",
        "journal": "The American Journal of Medicine",
        "pub_date": "2026-06-20",
        "topic": "Clinical Trials and Guidelines",
        "topic_num": 6,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Editorial",
        "findings": (
            "This observational editorial documents a growing pattern observed in community cardiology practice whereby hypertension management is increasingly being deferred or referred to cardiologists rather than being initiated and maintained in primary care settings. "
            "The authors identify therapeutic inertia in primary care—defined as failure to intensify treatment when blood pressure targets are not met—as a primary driver of inappropriate referrals to cardiology, contributing to system-level inefficiencies. "
            "Guideline non-adherence in primary care is highlighted as a persistent structural problem, with many hypertensive patients failing to receive guideline-recommended drug combinations or reaching BP targets before cardiology referral. "
            "Fragmented care delivery and patient complexity (multiple comorbidities, polypharmacy) are identified as additional systemic contributors that push hypertension management toward specialty care rather than being addressed in the primary care medical home. "
            "The editorial calls for better cardiovascular prevention strategies, strengthening of hypertension management competencies in primary care, and integration of structured hypertension management programs within general practice to address the growing burden on cardiology services. "
            "As an editorial, this work is opinion-based and lacks original quantitative data, which limits the strength of specific recommendations; however, it reflects real-world practice patterns observed by experienced clinicians."
        ),
        "implications": (
            "The described shift of hypertension management toward cardiologists has implications for guideline implementation strategies, suggesting that educational initiatives targeting primary care physicians on treatment intensification and guideline adherence are urgently needed. "
            "Medical Affairs should consider developing primary care-focused educational programs addressing therapeutic inertia in hypertension, including practical tools for BP target monitoring and stepped-care treatment algorithms tailored for non-specialist settings. "
            "This editorial highlights a system-level unmet need that Medical Affairs can address through partnerships with primary care medical associations to improve hypertension control rates and reduce avoidable specialist referrals."
        ),
    },
    {
        "pmid": "42324107",
        "title": "PRDX1 attenuates hypertensive endothelial dysfunction by inhibiting mTOR/p70S6K signaling",
        "journal": "Zhonghua Xin Xue Guan Bing Za Zhi",
        "pub_date": "2026-06-24",
        "topic": "Clinical Trials and Guidelines",
        "topic_num": 6,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Original Research",
        "findings": (
            "This experimental study used C57BL/6J mice subjected to chronic angiotensin II (AngII) infusion (0.8 mg/kg/day for 4 weeks) as a model of hypertension-induced endothelial dysfunction, investigating the role of Peroxiredoxin 1 (PRDX1) in vascular biology. "
            "PRDX1 protein expression was found to be significantly decreased in AngII-stimulated human umbilical vein endothelial cells (HUVECs), implicating oxidative stress-mediated PRDX1 downregulation in the pathogenesis of hypertensive endothelial injury. "
            "PRDX1 overexpression (via lentiviral vector LV-PRDX1) in HUVECs reduced mTOR and p70S6K phosphorylation, increased eNOS phosphorylation, and elevated nitric oxide (NO) production, collectively restoring endothelial function markers. "
            "Conversely, PRDX1 knockdown worsened endothelial dysfunction in AngII-treated cells, and this effect was reversed by rapamycin (mTOR inhibitor), confirming the mechanistic link between PRDX1 and the mTOR/p70S6K pathway. "
            "In vivo, AAV9-mediated PRDX1 overexpression in AngII-infused mice lowered systolic blood pressure, reduced aortic wall thickness, and improved endothelium-dependent vasodilation (acetylcholine response), with co-immunoprecipitation confirming a direct protein-protein interaction between PRDX1 and mTOR. "
            "Limitations include the use of a single animal model limiting translational relevance, absence of pharmacological PRDX1-targeting strategies tested, and the lack of human tissue validation of the PRDX1-mTOR interaction."
        ),
        "implications": (
            "The identification of PRDX1 as a regulator of mTOR-mediated endothelial dysfunction in hypertension establishes a novel molecular target for antihypertensive drug discovery, with the mTOR/p70S6K axis representing a druggable pathway that is already partially targeted by existing agents. "
            "From a Medical Affairs perspective, these mechanistic insights support scientific communications around the endothelial protective mechanisms of antihypertensive therapies, particularly those that influence oxidative stress and NO bioavailability beyond blood pressure reduction. "
            "Monitoring PRDX1-targeted research programs and engaging with vascular biology KOLs could position Medical Affairs to facilitate translation from preclinical findings to early-phase clinical investigation in hypertensive vascular disease."
        ),
    },
    {
        "pmid": "42323862",
        "title": "Adipose Tissue Depots and Blood Pressure Regulation: Mechanisms, Biomarkers, and Targets Beyond Obesity",
        "journal": "American Journal of Hypertension",
        "pub_date": "2026-06-20",
        "topic": "Clinical Trials and Guidelines",
        "topic_num": 6,
        "tier": "3",
        "if_estimate": "~4.5",
        "article_type": "Review",
        "findings": (
            "This narrative review systematically examines post-2020 literature on the role of six distinct adipose tissue depots—visceral, perivascular, epicardial, bone marrow, brown, and beige adipose tissue—in blood pressure regulation, reframing adipose tissue as a modular, depot-specific regulator of vascular tone. "
            "Each depot exerts distinct influences on blood pressure through unique endocrine, inflammatory, and exosome-dependent mechanisms: for example, perivascular adipose tissue directly modulates vascular tone through paracrine signaling, while epicardial adipose tissue influences cardiac autonomic regulation and coronary vasomotion. "
            "Adipose tissue dysfunction can impair nitric oxide signaling, promote oxidative stress, and modulate sympathetic nervous system tone even in the absence of generalized obesity, challenging the traditional view that adipose-related hypertension is exclusive to obese individuals. "
            "Exosomal microRNAs secreted by dysfunctional adipose tissue are identified as novel mediators of vascular homeostasis disruption, representing a new layer of inter-organ communication in hypertension pathophysiology. "
            "The review proposes a framework for adipose imaging biomarkers (e.g., epicardial fat volume by CT/MRI) and molecular profiling as tools for identifying patients at elevated vascular risk regardless of BMI, with potential for enabling targeted therapeutic strategies. "
            "As a narrative review, this work is subject to selection bias in literature choice and does not include systematic search methodology or meta-analytic rigor; the clinical translation of proposed biomarkers remains largely investigational."
        ),
        "implications": (
            "The depot-specific adipose framework challenges BMI-centric cardiovascular risk assessment and supports the development of imaging-based biomarker panels that could stratify hypertensive patients for targeted therapies regardless of weight category. "
            "Medical Affairs can leverage this review to support scientific narratives around antihypertensive therapies that favorably modulate perivascular or visceral adipose dysfunction, an increasingly important differentiator as metabolic hypertension phenotypes gain clinical recognition. "
            "Engaging KOLs in adipose biology, metabolic cardiology, and hypertension will be essential to advancing the clinical translation of depot-specific adipose biomarkers and establishing their role in therapeutic target identification and patient stratification."
        ),
    },
    {
        "pmid": "42323564",
        "title": "Social determinants of older adult suicide: an ecological study using data of Japanese secondary medical areas",
        "journal": "BMC Public Health",
        "pub_date": "2026-06-20",
        "topic": "Environment and Risk Factors",
        "topic_num": 7,
        "tier": "NA",
        "if_estimate": "NA",
        "article_type": "Original Research",
        "findings": (
            "This ecological study utilized publicly available Japanese mortality and socioeconomic data across secondary medical areas to analyze standardized mortality ratios (SMR) for suicide in adults aged 60 years and older, examining associations with lifestyle-related diseases, socioeconomic factors, and healthcare resource availability. "
            "Multiple regression analyses identified a positive association between suicide SMR and the prevalence of hypertension among older male adults, suggesting that the burden of chronic disease—including hypertension—may contribute to the socioecological risk landscape for late-life suicide. "
            "Additional positive predictors of higher suicide SMR included smoking prevalence, daily alcohol consumption, single-person older adult households, and higher male employment rates, pointing to a complex interplay of lifestyle and social isolation factors. "
            "Negative associations with suicide SMR were identified for psychiatrist/psychotherapist density (protective effect of mental health resources) and higher income per taxpayer among women, highlighting gender-specific socioeconomic determinants of late-life suicide risk. "
            "The identification of hypertension as part of the ecological risk profile for older adult suicide is notable and may reflect shared pathophysiology (depression, cognitive impairment, disability) or the psychosocial burden of managing chronic hypertensive disease in older age. "
            "Critical limitations include the ecological study design which precludes individual-level inference, the risk of ecological fallacy in interpreting area-level associations, and the cross-sectional nature of the data preventing causal conclusions."
        ),
        "implications": (
            "The association of hypertension with elevated ecological suicide risk in older adults reinforces the importance of integrated mental health screening within hypertension care pathways for elderly patients, an area where current clinical guidelines are largely silent. "
            "Medical Affairs teams should consider supporting educational programs that sensitize cardiologists and internists managing older hypertensive patients to signs of depression, social isolation, and suicide risk, particularly in markets with aging populations. "
            "This study's ecological findings should prompt further individual-level prospective research investigating the mediating role of hypertension-related disability and quality of life impairment in late-life mental health outcomes."
        ),
    },
]

def tier_badge(tier, if_est):
    if tier == "1":
        color = "#1a5276"
        label = f"Tier 1 — IF estimé : {if_est}"
    elif tier == "3":
        color = "#1e8449"
        label = f"Tier 3 — IF estimé : {if_est}"
    else:
        color = "#7f8c8d"
        label = "Tier NA"
    return f'<span style="background:{color};color:#fff;padding:2px 8px;border-radius:4px;font-size:11px;margin-left:8px;">{label}</span>'

def article_type_badge(atype):
    colors = {
        "Editorial": "#8e44ad",
        "Review": "#16a085",
        "Original Research": "#2980b9",
    }
    c = colors.get(atype, "#555")
    return f'<span style="background:{c};color:#fff;padding:2px 8px;border-radius:4px;font-size:11px;margin-left:4px;">{atype}</span>'

def render_article(a, letter):
    badge = tier_badge(a["tier"], a["if_estimate"])
    abadge = article_type_badge(a["article_type"])
    return f"""
    <div style="border:1px solid #d5d8dc;border-radius:6px;padding:16px;margin-bottom:18px;background:#fdfefe;">
      <h3 style="margin-top:0;color:#1a5276;">Article {a['topic_num']}-{letter} — PMID: {a['pmid']}{badge}{abadge}</h3>
      <p style="margin:4px 0;"><strong>Titre :</strong> {a['title']}</p>
      <p style="margin:4px 0;"><strong>Journal :</strong> <em>{a['journal']}</em> &nbsp;|&nbsp; <strong>Date :</strong> {a['pub_date']}</p>
      <div style="margin-top:12px;">
        <h4 style="color:#2874a6;margin-bottom:4px;">Analyse et résultats clés</h4>
        <p style="text-align:justify;">{a['findings']}</p>
      </div>
      <div style="margin-top:10px;background:#eaf4fb;border-left:4px solid #2980b9;padding:10px 14px;border-radius:0 4px 4px 0;">
        <h4 style="color:#1a5276;margin:0 0 6px 0;">Implications Medical Affairs</h4>
        <p style="margin:0;text-align:justify;">{a['implications']}</p>
      </div>
    </div>
"""

def no_articles_box(topic_name):
    return f"""
    <div style="background:#fef9e7;border:1px solid #f39c12;border-radius:6px;padding:14px;margin-bottom:18px;color:#7d6608;">
      <strong>Aucun article indexé sur PubMed pour le thème « {topic_name} » durant la période de veille.</strong>
    </div>
"""

topics = [
    (1, "Épidémiologie de l'Hypertension Artérielle"),
    (2, "Inhibiteurs de l'Enzyme de Conversion (IEC)"),
    (3, "Antagonistes des Récepteurs de l'Angiotensine II (ARA II / Sartans)"),
    (4, "Inhibiteurs Calciques"),
    (5, "Diurétiques et Bêta-bloquants"),
    (6, "Essais Cliniques et Recommandations"),
    (7, "Environnement et Facteurs de Risque"),
]

topic_letters = {}
topic_articles_map = {}
for a in articles_data:
    tn = a["topic_num"]
    if tn not in topic_articles_map:
        topic_articles_map[tn] = []
    topic_articles_map[tn].append(a)

letter_seq = "ABCDEFGHIJKLMNOPQRSTUVWXYZ"

sections_html = ""
for (tnum, tname) in topics:
    sections_html += f"""
  <h2 style="color:#1a5276;border-bottom:2px solid #aed6f1;padding-bottom:4px;">Thème {tnum} : {tname}</h2>
"""
    if tnum in topic_articles_map:
        for idx, art in enumerate(topic_articles_map[tnum]):
            letter = letter_seq[idx]
            sections_html += render_article(art, letter)
    else:
        sections_html += no_articles_box(tname)

html = f"""<!DOCTYPE html>
<html>
<body style="font-family: Arial, sans-serif; line-height: 1.6; color: #333; max-width: 900px; margin: auto; padding: 20px;">
  <h1 style="color: #1a5276;">Veille Scientifique &mdash; Hypertension Arterielle</h1>
  <p><strong>Date :</strong> 2026-06-22</p>
  <p><strong>Periode :</strong> Articles indexes sur PubMed dans les dernieres 24 heures</p>
  <p><strong>Total articles :</strong> 14 nouveaux articles sur 7 themes</p>
  <hr />
{sections_html}
  <hr />
  <p style="font-size: 12px; color: #777;">Digest generated automatically for internal medical monitoring. Source: PubMed/NCBI.</p>
</body>
</html>"""

output_path = "/home/user/Veille-scientifique/digest_2026-06-22.html"
with open(output_path, "w", encoding="utf-8") as f:
    f.write(html)

size = os.path.getsize(output_path)
print(f"File written: {output_path}")
print(f"File size: {size} bytes")

archive_entries = []
for a in articles_data:
    archive_entries.append({
        "pmid": a["pmid"],
        "title": a["title"],
        "journal": a["journal"],
        "pub_date": a["pub_date"],
        "topic": a["topic"],
        "topic_num": a["topic_num"],
        "tier": a["tier"],
        "if_estimate": a["if_estimate"],
        "article_type": a["article_type"],
        "digest_date": "2026-06-22",
        "digest_file": "digest_2026-06-22.html"
    })

print("\nArchive JSON entries:")
print(json.dumps(archive_entries, indent=2, ensure_ascii=False))
